Low-CBFA2T3 expression predicts favorable prognosis in t(8;21) AML but not non-CBF AML. (A) Kaplan-Meier analyses of relapse-free and overall survival of t(8;21) and non-CBF patients expressing high and low CBFA2T3 (GSE14468). The P value shown at the left bottom corner is derived from comparison of all sample groups (log-rank test). (B) Relapse potentials of t(8;21) and non-CBF AML patients expressing CBFA2T3 below or above different quantile levels shown at the bottom (GSE14468). For each quantile, the y-axis denotes log2 ratios of relapsed vs event-free survival (EFS) patients expressing CBFA2T3 below or above the quantile level measured independently for t(8;21) and non-CBF AML patients. P values were derived from the hypergeometric test. (C-D) Levels of CBFA2T3 expression among different AML FAB subtypes (C) and karyotypes (D). In panel D, the P values were calculated between patients with and without each of given karyotypes. (E) CBFA2T3 expression levels in PML-RARα–expressing NB4 cells treated with dimethyl sulfoxide or ATRA (RA). (F) Venn diagram showing overlap of FAB M4/M5, low-CBFA2T3 non-CBF, and cytogenetically normal AML subtypes (GSE14468). *P < .05; **P < .01; ***P < .001. n.s., not significant.